February 16,2006

Senator Grassley's Statement for the Record regarding FDA's Approval Process

Please see the following two documents attached as related files:

(1) Grassley Statement from the Feb. 16 Congressional Record
(2) Report of the Committee Staff Review of the FDA’s Approval Process for the Vagus Nerve Stimulation Therapy System for Treatment-Resistant Depression

Next Article Previous Article

Recent News

11/20/24 Crapo Joins Fox Business to Talk Taxes
11/19/24 Crapo Statement on Announcement of Intent to Nominate Dr. Mehmet Oz to Head CMS
11/14/24 Crapo Statement on Announcement of Intent to Nominate Robert F. Kennedy Jr. to Head HHS
11/14/24 Crapo Statement at Hearing to Consider Treasury Inspector General for Tax Administration
10/30/24 Crapo, Smith Statement on Biden Administration’s Taiwan Double-Tax Relief Announcement